Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas

Novartis AG (NYSE:NVS) is one of the top gene therapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) ...
Bar and Bench

Touchstone, AZB, Freshfields act on sale of Novartis India by Novartis AG

Novartis AG has sold its entire shareholding of Novartis India Limited, representing 70.68% of the equity share capital, to WaveRise Investments Limited, ChrysC ...

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks ...
The Financial Express

ChrysCapital-led consortium to acquire majority stake in Novartis India for Rs 1446 crore

The deal, expected to close by Q3 2026, includes a mandatory open offer for public shareholders at ₹860.64 per share.

Novartis shares hit 20% upper circuit as Swiss parent to sell entire stake

Novartis India shares hit 20% upper circuit after the Novartis AG has agreed to sell 17.4 million fully paid-up equity shares, representing 70.68 per cent equity of Novartis India, to a consortium ...

Novartis Pharma AG: Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...
Hosted on MSN

What Makes Novartis AG (NVS) a Differentiated Business?

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund ...
Hosted on MSN

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?

Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $12.86 billion, while the same for ...
Novartis

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Phase III program in food allergy (FA) planned for H2 2026 ...
AOL

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of ...

Novartis AG to exit listed India unit in $159 mn deal with ChrysCapital

Novartis AG will sell its entire 70.68% stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, triggering an open offer that could take the deal size to nearly Rs 2,000 crore ...
Benzinga.com

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead

Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday. The company's net sales rose 1% year over year to $13.34 billion, missing Wall Street's consensus ...